Drugs / Adadelimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07542002 | Mar 2025 → May 2026 overdue | malignant exocrine pancreas neoplasm | Ningbo Medical Center Lihuili Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adadelimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07542002 ↗ |
| Route | Intravenous | “Adadelimab: 1200 mg administered via intravenous infusion over 30-60 minutes on Day 1, every 4 weeks.” NCT07542002 ↗ |